Should amylin have been obesity therapeutics’ primary target from the start?

Analysts argue amylin should have become the primary obesity target earlier, as it may be better tolerated than GLP-1 drugs. Novo Nordisk's CagriSema achieved 22.7% weight loss at 68 weeks in the REDEFINE-1 trial, and the FDA has accepted the filing; Eli Lilly's EloraTZP showed 23.3% weight loss at 48 weeks in Phase II (Zepbound alone 14.8%, placebo 3%), but adverse-event-related discontinuation rates of 10.8%-27% give mixed safety data.